58 episodes

Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.

eCysticFibrosis Review eCysticFibrosis Review

    • Medicine
    • 4.0 • 3 Ratings

Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.

    Bringing Telemedicine to the CF Clinic: A Success Story

    Bringing Telemedicine to the CF Clinic: A Success Story

    Take our post-test to claim CME credits.







    No-contact telemedicine to better protect CF clinic patients and staff during this pandemic may sound like a great idea, but is it even possible to institute? In this eCysticFibrosis Review Special Edition podcast, we find out how pulmonary and critical care specialists Dr. Dana Albon and Dr. Lindsay Somerville successfully brought telemedicine to their Adult Cystic Fibrosis Clinic at University of Virginia Health.

    • 24 min
    CFTR, Growth & Liver Disease: A Clinical Perspective

    CFTR, Growth & Liver Disease: A Clinical Perspective

    Take our post-test to claim CME credits.







    To read a companion newsletter click here.







    Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What’s known about CFTR modulator effects on cystic fibrosis-associated liver disease?  







    In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Division of Gastroenterology, Hepatology, and Nutrition at the Johns Hopkins Children’s Center take us to the clinic to answer these and other questions crucial to the health of our patients with cystic fibrosis. 

    • 20 min
    In the Clinic: Triple Combination CFTR Modulation

    In the Clinic: Triple Combination CFTR Modulation

    Take our post-test to claim CME credits.







    To read a companion newsletter click here.







    Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy.  What are the benefits?  For which patients?  What are the potential adverse effects?  Who’s most likely to receive them?  







    In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers. 

    • 25 min
    Addressing Mental Health in CF

    Addressing Mental Health in CF

    Take our post-test to claim CME credits.







    To read a companion newsletter click here.







    Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work?







    In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psychiatrist, Massachusetts General Hospital Cystic Fibrosis Program, takes us to the clinic to answer these questions that can be key to the health and well-being of children, adults, and families living with CF.

    • 20 min
    Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

    Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

    New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 21 min
    Continuous Alternating Therapies: A Clinical Perspective

    Continuous Alternating Therapies: A Clinical Perspective

    Volume 8, Issue 11.







    In this issue:







    Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents?  Which medications are appropriate for continuous alternating therapy (CAT)?







    In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 21 min

Customer Reviews

4.0 out of 5
3 Ratings

3 Ratings

andefined ,

Testing

Testing

Top Podcasts In Medicine